Stanley Gutiontov1, Jonathan Leeman1, Benjamin Lok1, Paul Romesser1, Nadeem Riaz1, C Jillian Tsai1, Nancy Lee1, Sean McBride2. 1. Memorial Sloan Kettering Cancer Center, Department of Radiation Oncology, 1250 First Avenue, Schwartz Building Mezzanine, New York, NY 10065, United States. 2. Memorial Sloan Kettering Cancer Center, Department of Radiation Oncology, 1250 First Avenue, Schwartz Building Mezzanine, New York, NY 10065, United States. Electronic address: mcbrides@mskcc.org.
Abstract
OBJECTIVES: Patients treated with definitive chemoradiation for oropharyngeal squamous cell carcinoma (OPC) experience excellent outcomes but treatment toxicities remain significant. The adoption of intensity modulated radiation therapy (IMRT) reduced morbidity by allowing targeting of at risk areas while sparing uninvolved regions. We explored whether level V lymphatics (LVN) can be omitted from elective volumes in OPC. MATERIALS AND METHODS: This analysis included 408 patients treated for stage III/IV OPC with IMRT at our institution. For 295 (72.3%) patients, bilateral LVN were covered, while LVN were omitted in 113 (27.7%). Nodal staging was N2a or greater in 324 patients (79.4%). All but one received concurrent chemotherapy. Actuarial regional recurrence was calculated using the KM method with the event of interest defined as any regional recurrence; all others were censored. Univariate and multivariate analyses were performed on variables significantly associated with both the inclusion of elective LVN and regional recurrence. RESULTS: After a median follow-up of 63.6months (range, 1.3-125months), there were no level V failures in either group. The 2-year cumulative rate of regional failure (RF) was 4.5% (95% CI=2.9-6.6) in the overall cohort, 2.2% (95% CI=0.1-5.9) in the LVN untreated group, and 5.4% (95% CI=3.4-8.1) in the LVN treated group. After adjusting for Stage and tobacco status, there was no significant difference between the two groups in RF (HR=1.75 95% CI=(0.61-5.07), p=0.30). CONCLUSION: LVN can be safely omitted from the clinical target volume in locally advanced OPC without gross LVN involvement.
OBJECTIVES:Patients treated with definitive chemoradiation for oropharyngeal squamous cell carcinoma (OPC) experience excellent outcomes but treatment toxicities remain significant. The adoption of intensity modulated radiation therapy (IMRT) reduced morbidity by allowing targeting of at risk areas while sparing uninvolved regions. We explored whether level V lymphatics (LVN) can be omitted from elective volumes in OPC. MATERIALS AND METHODS: This analysis included 408 patients treated for stage III/IV OPC with IMRT at our institution. For 295 (72.3%) patients, bilateral LVN were covered, while LVN were omitted in 113 (27.7%). Nodal staging was N2a or greater in 324 patients (79.4%). All but one received concurrent chemotherapy. Actuarial regional recurrence was calculated using the KM method with the event of interest defined as any regional recurrence; all others were censored. Univariate and multivariate analyses were performed on variables significantly associated with both the inclusion of elective LVN and regional recurrence. RESULTS: After a median follow-up of 63.6months (range, 1.3-125months), there were no level V failures in either group. The 2-year cumulative rate of regional failure (RF) was 4.5% (95% CI=2.9-6.6) in the overall cohort, 2.2% (95% CI=0.1-5.9) in the LVN untreated group, and 5.4% (95% CI=3.4-8.1) in the LVN treated group. After adjusting for Stage and tobacco status, there was no significant difference between the two groups in RF (HR=1.75 95% CI=(0.61-5.07), p=0.30). CONCLUSION: LVN can be safely omitted from the clinical target volume in locally advanced OPC without gross LVN involvement.
Authors: Chad M McDuffie; Nazanin Amirghahari; Gloria Caldito; Timothy S Lian; Luke Thompson; Cherie-Ann O Nathan Journal: Laryngoscope Date: 2005-12 Impact factor: 3.325
Authors: Pranshu Mohindra; Erich Urban; Jonathan D Pagan; Heather M Geye; Vatsal B Patel; R Adam A Bayliss; Edward T Bender; Paul M Harari Journal: Head Neck Date: 2015-06-16 Impact factor: 3.147
Authors: Anil K Chaturvedi; Eric A Engels; Ruth M Pfeiffer; Brenda Y Hernandez; Weihong Xiao; Esther Kim; Bo Jiang; Marc T Goodman; Maria Sibug-Saber; Wendy Cozen; Lihua Liu; Charles F Lynch; Nicolas Wentzensen; Richard C Jordan; Sean Altekruse; William F Anderson; Philip S Rosenberg; Maura L Gillison Journal: J Clin Oncol Date: 2011-10-03 Impact factor: 44.544
Authors: Jeremy Setton; Nicola Caria; Jonathan Romanyshyn; Lawrence Koutcher; Suzanne L Wolden; Michael J Zelefsky; Nicholas Rowan; Eric J Sherman; Matthew G Fury; David G Pfister; Richard J Wong; Jatin P Shah; Dennis H Kraus; Weiji Shi; Zhigang Zhang; Karen D Schupak; Daphna Y Gelblum; Shyam D Rao; Nancy Y Lee Journal: Int J Radiat Oncol Biol Phys Date: 2010-12-16 Impact factor: 7.038
Authors: Klaudia U Hunter; Francis Worden; Carol Bradford; Mark Prince; Scott McLean; Gregory Wolf; Douglas B Chepeha; Avraham Eisbruch Journal: Head Neck Date: 2013-04-04 Impact factor: 3.147
Authors: K S Clifford Chao; Gokhan Ozyigit; Binh N Tran; Mustafa Cengiz; James F Dempsey; Daniel A Low Journal: Int J Radiat Oncol Biol Phys Date: 2003-02-01 Impact factor: 7.038
Authors: Jonathan E Leeman; Jin-Gao Li; Xin Pei; Praveen Venigalla; Zachary S Zumsteg; Evangelia Katsoulakis; Eitan Lupovitch; Sean M McBride; Chiaojung J Tsai; Jay O Boyle; Benjamin R Roman; Luc G T Morris; Lara A Dunn; Eric J Sherman; Nancy Y Lee; Nadeem Riaz Journal: JAMA Oncol Date: 2017-11-01 Impact factor: 31.777